Small-Cap Insider Buying: 3 Clusters Worth Watching (July 30, 2026)

Cluster buying — two or more insiders purchasing their own company’s stock within a short window — is one of the few public signals with real information behind it. One insider buying can mean anything: a scheduled plan, a gesture, a rounding error in a large net worth. Several insiders buying together, with their own cash, at the same moment, is harder to dismiss.

Each week this screen surveys the past two weeks of SEC Form 4 filings for purchase clusters, drops everything above roughly $2 billion in market value, and — the step most aggregators skip — reads the actual filings on EDGAR before drawing conclusions. This week, that last step mattered: the biggest “cluster” on the tape wasn’t what it appeared to be. Here is what survived.

1. Byrna Technologies (NASDAQ: BYRN) — the C-suite buys the crash

Five insiders · ~$305,000 · open market at $3.40–$3.86 · July 23–28

Three weeks ago, Byrna — the less-lethal personal-defense company behind the Byrna launcher — reported a fiscal second quarter it would rather forget: revenue of $16.4 million, down from $28.5 million a year earlier, and a net loss of $10.1 million. The stock, which traded as high as $30.62 within the past year, fell into the mid-$3s. CEO Conn Davis was blunt about it:

“Our second quarter results did not reflect the level of performance we believe Byrna can deliver.”

Then the buying started. Between July 23 and July 28, five insiders bought roughly $305,000 of stock in the open market at $3.40–$3.86: Davis himself (about $77,000), CFO Laurilee Kearnes, and directors TJ Kennedy (about $102,000), Herbert Hughes (two separate purchases totaling about $89,000), and Chris Reed. Every featured filing is a plain code-P open-market purchase — we checked each one on EDGAR.

The balance sheet gives the bet room to work: $10.4 million in cash, no debt, and a small bolt-on acquisition of Hero Defense Systems’ assets closed in early July. At $4.38 — a market value of about $99 million on 22.7 million shares — the stock already sits above every price paid in the cluster. Whatever the market ultimately decides about the turnaround, the two executives closest to the numbers and three board members have put their own cash behind it, on the record.

2. Columbia Financial (NASDAQ: CLBK) — the leadership subscribes at $10.00

14+ insiders · ~$4.2 million verified · subscription at $10.00 · July 20

This one is a special situation rather than a classic open-market cluster — and it’s the most interesting set of filings on the week’s tape. On July 20, Columbia Financial completed its second-step conversion from the mutual holding company structure, a $1.7 billion stock offering at $10.00 per share, and simultaneously closed its merger with Northfield Bancorp — creating an $18.0 billion-asset bank spanning New Jersey, Staten Island, and Brooklyn.

The Form 4s show the leadership team subscribing in that offering at the $10.00 conversion price, essentially in unison: CEO Thomas Kemly ($530,570), CFO Thomas Splaine ($500,000), COO Steven Klein ($500,000), the heads of consumer and commercial banking, and most of the board — at least 14 filers and roughly $4.2 million that we verified filing-by-filing, with aggregate trackers putting the full cluster near $4.8 million across 16 insiders. Newly converted thrifts bought at the $10 offering price are one of the oldest playbooks in small-bank investing, and full-roster insider participation is exactly what that playbook looks for. The shares closed at $10.96, about 10% above the offering price. The combined company has outgrown a strict small-cap label, so it appears here as the week’s special situation rather than a screen pick.

3. Rhinebeck Bancorp (NASDAQ: RBKB) — buying near the highs

Four insiders · ~$656,000 · open market at $11.92–$12.00 · July 22

Insider clusters usually show up after a stock has fallen. Rhinebeck Bancorp — a $139 million Hudson Valley bank holding company — is the opposite case. On July 22, President & CEO Matthew Smith (about $149,000), directors Nancy Patzwahl (about $299,000) and Suzanne Loughlin (about $149,000), and commercial-banking head Michael Vitale (about $60,000) bought roughly $656,000 of stock in the open market at $11.92–$12.00 — within a few percent of the 52-week high of $12.88, and nearly double the 52-week low of $6.74. Buying weakness is contrarian conviction; buying strength says the people who set the budget don’t think the move is finished.

Screened out: the $71 million mirage

The largest “cluster” on this week’s tape was Scribe Therapeutics (NASDAQ: SCTX), showing more than $71 million of insider “purchases” across six filers. Read the filings and the picture changes: the footnotes disclose shares bought from the underwriters in the company’s offering, preferred stock converting into common, and transactions that predate the company’s registration. That is IPO mechanics — funds and insiders participating in a new listing — not discretionary open-market accumulation. It’s the reason this screen reads footnotes before headlines.

Also in the window, excluded on size: multi-insider purchase filings at Albertsons (ACI), Elevance Health (ELV), Taiwan Semiconductor (TSM), and Goosehead Insurance (GSHD) — all well above the small-cap line.

Methodology

Universe: SEC Form 4 filings for U.S.-listed common stocks, trailing 14 days. Signal: two or more distinct insiders reporting purchases (transaction code P). Filters: market capitalization under roughly $2 billion; offering- and conversion-driven purchases identified from filing footnotes and treated separately from open-market clusters. Every featured filing was verified directly against SEC EDGAR. Prices, market values, and 52-week ranges are as of July 30, 2026. Sources: SEC EDGAR filings, aggregated Form 4 screening data, and exchange market data.

Disclosure

Small Cap Newsroom is a research publication, not an investment adviser, and nothing here is investment advice or a recommendation to buy or sell any security. Insider purchases are one input among many and do not predict returns. The author may hold positions in securities mentioned. Do your own research.